摘要
目的:观察精乌胶囊联合贝那普利对2型糖尿病肾病尿白蛋白排泄率(UAER)及血肌酐(Cr)水平的影响。方法:将60例2型糖尿病肾病患者按随机数字表法分为对照组和观察组,各30例。对照组患者4例失访,1例因出现刺激性干咳退出研究;观察组患者4例失访。对照组患者口服贝那普利氢氯噻嗪片5 mg,qd;观察组在对照组基础上加服精乌胶囊2.7 g,tid。两组患者均治疗12周。观察两组患者治疗前后UAER、Cr水平及不良反应情况。结果:治疗前,两组患者UAER水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者UAER水平显著降低且低于对照组,差异有统计学意义(P<0.05)。两组患者治疗前后Cr水平比较,差异无统计学意义(P>0.05)。治疗后,对照组患者出现刺激性干咳1例,观察组患者未见明显不良反应发生。结论:精乌胶囊联合贝那普利能明显降低2型糖尿病肾病患者UAER,不加重患者肾脏负担,安全性较好。
OBJECTIVE:To observe the effect of urinary albumin excretion rate(UAER) and serum creatinine(Cr) level of Jingwu capsule combined with benazepril in the treatment of urinary microalbumin of type 2 diabetic nephropathy. METHODS:60patients with urinary microalbumin of type 2 diabetic nephropathy were randomly divided into control group and observation group,with 30 cases in each group. There were 4 cases of follow-up failure and 1 case of irritant dry cough in control group;there were 4cases of follow-up failure in observation group. Control group was given benazepril 5 mg,qd;observation group was additionally given Jingwu capsule 2.7 g,tid,on the basis of control group. Both group were treated for 12 weeks. UAER and Cr level,ADR were observed in 2 groups before and after treatment. RESULTS:Before treatment,there was no statistical significance in UAER level between 2 groups(P>0.05);after treatment,UAER level of observation group was significantly lower than that of control group,with statistical significance(P<0.05). There was no statistical significance in Cr level between 2 groups before and after treatment(P>0.05). After treatment,one patient of control group suffered from irritant dry cough,and no obvious ADR was found in observation group. CONCLUSIONS:Jingwu capsule combined with benazepril can decrease urinary albumin in patient with type 2 diabetic nephropathy and doesn't incease the burden on pationts with renal with good safety.
引文
[1]Ha H,Kim KH.Pathogenesis of diabetic nephropathy:the role of oxidative stress and protein kinase C[J].Diabetes Res Clin Pract,1999,45(2/3):147.
[2]薛福平,袁慧欣,郭丽君,等.坎地沙坦脂联合地黄叶总苷治疗早期糖尿病肾病疗效观察[J].武警医学,2013,24(10):857.
[3]贾学元.伊贝沙坦与复方丹参联合应用对早期糖尿病肾病患者肾功能及血液流变学的影响[J].实用医院临床杂志,2013,10(4):152.
[4]Alberti KG,Zimmet PZ.Definition,diagnosis and classification of diabetes mellitus and its complications:report of a WHO consultation.Part I:diagnosis and classification of diabetes mellitus.Provisional report of WHD consultation[J].Diabet Med,1998,15(7):539.
[5]Remuzzi G,Schieppati A,Ruggenenti P.Clinical practice.Nephropathy in patients with type 2 diabetes[J].NEngl J Med,2002,346(15):1 145.
[6]Chen Y,Wang M,Rosen RT,et al.2,2-Diphenyl-1-picrylhydrazyl radical-scavenging active cmponents from polygonum multiflorum thunb[J].J Agric Food Chem,1999,47(6):2 226.
[7]相聪坤,王蕊,袁志芳.何首乌二苯乙烯苷类提取物对高脂血症大鼠血脂代谢的影响及其抗氧化作用[J].中国药业,2009,18(24):19.
[8]张媛英,翟静,孙凌云,等.何首乌提取物对大鼠脑缺血再灌注损伤的保护作用[J].中国临床康复,2005,9(33):86.
[9]姚新生.天然药物化学[M].3版.北京:人民卫生出版社,2000:140.
[10]Kamiyama M,Urushihara M,Morikawa T,et al.Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy[J].Int J Mol Sci,2013,14(11):23 045.